2seventy bio与百时美施贵宝停止多发性骨髓瘤疗法试验 预计节省8000万美元
据了解，2seventy bio和其合作伙伴百时美施贵宝宣布，将停止新诊断的多发性骨髓瘤患者使用的T细胞免疫疗法Abecma的III期临床试验。这项名为KarMMa-9的研究，旨在评估Abecma与来那度胺联合治疗，以及来那度胺单药治疗的效果。两家公司表示，这一决定是在对该研究的商业理由进行彻底审查后做出的。
Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial
(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...
FiercePharma2 天
Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma trial in first-line ...
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
生物谷3 天
Clin Cancer Res：新研究表明CAR-T细胞治疗后继发性癌症的风险可能与 ...
据研究报告，在接受 CAR-T 细胞治疗之前，患者接受过中位数超过三种疗法的 SPM 风险明显高于之前接受过少于三种疗法的患者。同样，在随访时间低于中位数 21.7 个月的研究中，SPM 的发生率为 ...
Zacks.com on MSN1 天
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
TSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...
阿思達克財經網2 天
2seventy bio(TSVT.US)与百时美施贵宝(BMY.US)停止多发性骨髓瘤疗法试验 ...
据了解，2seventy ...
2seventy bio和百时美施贵宝暂停三期研究，预计节省成本
CAMBRIDGE, Mass. - 2seventy bio, Inc. (NASDAQ:TSVT)和百时美施贵宝公司(NYSE:BMY)联合宣布停止招募KarMMa-9三期研究。该研究旨在评估Abecma联合来那度胺维持治疗对自体干细胞移植后反应不佳的新诊断多发性骨髓瘤(NDMM)患者的疗效。 这一决定预计将在未来几年为2seventy bio节省超过8000万美元，并加速公司在2025年实现 ...
Pharmabiz18 小时
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of ...
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma ...
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
Business Wire2 天
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third ...
Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
Leerink Partners上调2Seventy Bio股票目标价
Leerink Partners调整了对2Seventy Bio Inc. (NASDAQ: TSVT)的展望，将该股票的目标价从之前的15.00美元上调至25.00美元，同时维持"优于大市"评级。 此次调整是在KarMMa-9试验终止后做出的，该试验原本预计将成为自体BCMA CAR-T疗法Abecma收入增长的重要贡献者。 根据Leerink Partners的分析，尽管KarMMa-9试验终 ...